Literature DB >> 27317352

An optogenetic mouse model of rett syndrome targeting on catecholaminergic neurons.

Shuang Zhang1, Christopher M Johnson1, Ningren Cui1, Hao Xing1, Weiwei Zhong1, Yang Wu1, Chun Jiang1.   

Abstract

Rett syndrome (RTT) is a neurodevelopmental disorder affecting multiple functions, including the norepinephrine (NE) system. In the CNS, NE is produced mostly by neurons in the locus coeruleus (LC), where defects in intrinsic neuronal properties, NE biosynthetic enzymes, neuronal CO2 sensitivity, and synaptic currents have been reported in mouse models of RTT. LC neurons in methyl-CpG-binding protein 2 gene (Mecp2) null mice show a high rate of spontaneous firing, although whether such hyperexcitability might increase or decrease the NE release from synapses is unknown. To activate the NEergic axonal terminals selectively, we generated an optogenetic mouse model of RTT in which NEergic neuronal excitability can be manipulated with light. Using commercially available mouse breeders, we produced a new strain of double-transgenic mice with Mecp2 knockout and channelrhodopsin (ChR) knockin in catecholaminergic neurons. Several RTT-like phenotypes were found in the tyrosine hydroxylase (TH)-ChR-Mecp2(-/Y) mice, including hypoactivity, low body weight, hindlimb clasping, and breathing disorders. In brain slices, optostimulation produced depolarization and an increase in the firing rate of LC neurons from TH-ChR control mice. In TH-ChR control mice, optostimulation of presynaptic NEergic neurons augmented the firing rate of hypoglossal neurons (HNs), which was blocked by the α-adrenoceptor antagonist phentolamine. Such optostimulation of NEergic terminals had almost no effect on HNs from two or three TH-ChR-Mecp2(-/Y) mice, indicating that excessive excitation of presynaptic neurons does not benefit NEergic modulation in mice with Mecp2 disruption. These results also demonstrate the feasibility of generating double-transgenic mice for studies of RTT with commercially available mice, which are inexpensive, labor/time efficient, and promising for cell-specific stimulation.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  AB_10049285; AB_10055152; AB_2337237; AB_2566814; AB_258613; IMR_JAX:008601; IMSR_JAX:003890; IMSR_JAX:012569; Mecp2; NE modulation; Rett syndrome; SCR_011323; double transgenic; optogenetics

Mesh:

Substances:

Year:  2016        PMID: 27317352      PMCID: PMC4990462          DOI: 10.1002/jnr.23760

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  22 in total

1.  [Noradrenaline deficiency as the origin of respiratory disorders in Rett syndrome an animal model].

Authors:  Laurent Villard; Jean-Christophe Roux
Journal:  Med Sci (Paris)       Date:  2006-01       Impact factor: 0.818

2.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

Authors:  J Guy; B Hendrich; M Holmes; J E Martin; A Bird
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

3.  Cerebrospinal fluid biogenic amines and biopterin in Rett syndrome.

Authors:  H Y Zoghbi; S Milstien; I J Butler; E O Smith; S Kaufman; D G Glaze; A K Percy
Journal:  Ann Neurol       Date:  1989-01       Impact factor: 10.422

4.  Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

Authors:  Eric K Richfield; Mona J Thiruchelvam; Deborah A Cory-Slechta; Charles Wuertzer; Raul R Gainetdinov; Marc G Caron; Donato A Di Monte; Howard J Federoff
Journal:  Exp Neurol       Date:  2002-05       Impact factor: 5.330

5.  Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice.

Authors:  Jean-Charles Viemari; Jean-Christophe Roux; Andrew K Tryba; Véronique Saywell; Henri Burnet; Fernando Peña; Sébastien Zanella; Michelle Bévengut; Magali Barthelemy-Requin; Laura B K Herzing; Anne Moncla; Josette Mancini; Jan-Marino Ramirez; Laurent Villard; Gérard Hilaire
Journal:  J Neurosci       Date:  2005-12-14       Impact factor: 6.167

6.  Diversity of transgenic mouse models for selective targeting of midbrain dopamine neurons.

Authors:  Stephan Lammel; Elizabeth E Steinberg; Csaba Földy; Nicholas R Wall; Kevin Beier; Liqun Luo; Robert C Malenka
Journal:  Neuron       Date:  2015-01-21       Impact factor: 17.173

7.  Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): implications for Lewy body disorders.

Authors:  George K Tofaris; Pablo Garcia Reitböck; Trevor Humby; Sarah L Lambourne; Mark O'Connell; Bernardino Ghetti; Helen Gossage; Piers C Emson; Lawrence S Wilkinson; Michel Goedert; Maria Grazia Spillantini
Journal:  J Neurosci       Date:  2006-04-12       Impact factor: 6.167

8.  Reduction of biogenic amine levels in the Rett syndrome.

Authors:  H Y Zoghbi; A K Percy; D G Glaze; I J Butler; V M Riccardi
Journal:  N Engl J Med       Date:  1985-10-10       Impact factor: 91.245

9.  A toolbox of Cre-dependent optogenetic transgenic mice for light-induced activation and silencing.

Authors:  Linda Madisen; Tianyi Mao; Henner Koch; Jia-min Zhuo; Antal Berenyi; Shigeyoshi Fujisawa; Yun-Wei A Hsu; Alfredo J Garcia; Xuan Gu; Sebastien Zanella; Jolene Kidney; Hong Gu; Yimei Mao; Bryan M Hooks; Edward S Boyden; György Buzsáki; Jan Marino Ramirez; Allan R Jones; Karel Svoboda; Xue Han; Eric E Turner; Hongkui Zeng
Journal:  Nat Neurosci       Date:  2012-03-25       Impact factor: 24.884

10.  Identification of a Group of GABAergic Neurons in the Dorsomedial Area of the Locus Coeruleus.

Authors:  Xin Jin; Shanshan Li; Brian Bondy; Weiwei Zhong; Max F Oginsky; Yang Wu; Christopher M Johnson; Shuang Zhang; Ningren Cui; Chun Jiang
Journal:  PLoS One       Date:  2016-01-19       Impact factor: 3.240

View more
  4 in total

1.  Optimized Administration of the M4 PAM VU0467154 Demonstrates Broad Efficacy, but Limited Effective Concentrations in Mecp2+/- Mice.

Authors:  Jakub Cikowski; Calista Holt; Bright Arthur; Mackenzie Smith; Sonia Gonzalez; Craig W Lindsley; Colleen M Niswender; Rocco G Gogliotti
Journal:  ACS Chem Neurosci       Date:  2022-06-07       Impact factor: 5.780

2.  Clinical and Preclinical Evidence for M1 Muscarinic Acetylcholine Receptor Potentiation as a Therapeutic Approach for Rett Syndrome.

Authors:  Mackenzie Smith; Bright Arthur; Jakub Cikowski; Calista Holt; Sonia Gonzalez; Nicole M Fisher; Sheryl Anne D Vermudez; Craig W Lindsley; Colleen M Niswender; Rocco G Gogliotti
Journal:  Neurotherapeutics       Date:  2022-06-07       Impact factor: 6.088

3.  Defects in brainstem neurons associated with breathing and motor function in the Mecp2R168X/Y mouse model of Rett syndrome.

Authors:  Christopher M Johnson; Weiwei Zhong; Ningren Cui; Yang Wu; Hao Xing; Shuang Zhang; Chun Jiang
Journal:  Am J Physiol Cell Physiol       Date:  2016-09-21       Impact factor: 4.249

4.  Effects of early-life exposure to THIP on brainstem neuronal excitability in the Mecp2-null mouse model of Rett syndrome before and after drug withdrawal.

Authors:  Weiwei Zhong; Christopher M Johnson; Ningren Cui; Max F Oginsky; Yang Wu; Chun Jiang
Journal:  Physiol Rep       Date:  2017-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.